Vision
Retinitis Pigmentosa
Retinitis Pigmentosa is a condition in the vision category. It is a specific named condition rather than a general description of vision concerns.
A focused starting point for understanding Retinitis Pigmentosa and its place among vision conditions.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Red Light Therapy (Photobiomodulation)practiceNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A 2024 pilot study involving 12 people found improved BCVA and trends in visual field, without adverse effects reported in the study.
Open the Red Light Therapy (Photobiomodulation) page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesRed Light Therapy (Photobiomodulation)CertaintyLowSourceClinical
A 2024 pilot study involving 12 people found improved BCVA and trends in visual field, without adverse effects reported in the study.
Who was studied
- People with a condition
Open Red Light Therapy (Photobiomodulation)Study result
Pilot study showing significant improvement in BCVA and trends in visual field without adverse effects.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Retinitis Pigmentosa worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Retinitis Pigmentosa is a condition in the vision category. It is a specific named condition rather than a general description of vision concerns. This reference provides a focused starting point for understanding the condition and its place among vision conditions.
Evidence-backed options
No evidence-backed options are listed for Retinitis Pigmentosa in this reference. Because this is a medical condition, treatment decisions and any questions about possible options are best discussed with a qualified clinician.
What to avoid
Vitamin E is flagged for avoidance in Retinitis Pigmentosa because high-dose supplementation has been associated with accelerated electroretinographic decline. In a major retinitis pigmentosa trial, Vitamin E at 400 IU/day accelerated this decline, which is why pharmacologic-dose supplementation is treated differently from routine nutritional intake.
This concern is specific to high-dose use and does not establish that every form or amount of Vitamin E has the same effect. Pharmacologic-dose supplementation should be avoided unless it is directed by a specialist. Anyone with Retinitis Pigmentosa considering Vitamin E should discuss the product and dose with a clinician familiar with their care.